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(57) ABSTRACT 
Water soluble macromers are modified by addition of free 
radical polymerizable groups, Such as those containing a 
carbon-carbon double or triple bond, which can be poly 
merized under mild conditions to encapsulate tissues, cells, 
or biologically active materials. The polymeric materials are 
particularly useful as tissue adhesives, coatings for tissue 
lumens including blood vessels, coatings for cells Such as 
islets of Langerhans, and coatings, plugs, Supports or Sub 
Strates for contact with biological materials Such as the body, 
and as drug delivery devices for biologically active mol 
ecules. A medical condition at a localized site is treated by 
applying a polymerization initiator and then applying a 
Substantially water-Soluble, degradable macromer of at least 
200 mw and having at least two crosslinkable substituents, 
and polymerizing the macromer to form a crosslinked poly 
meric material at the Site. The crosslinked polymeric mate 
rial may adhere two Surfaces together, or be a barrier that 
provides immunoisolation or prevents adhesion of the Site to 
another Surface Such as post-Surgical adhesion. A biologi 
cally active material may be present when the macromer is 
polymerized to provide for delivery of the biologically 
active material, or to provide the polymeric material with a 
desired property Such as resistance to bacterial growth or a 
decrease in inflammatory response. 
17 Claims, 7 Drawing Sheets 
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TREATING MEDICAL CONDITIONS BY 
POLYMERIZING MACROMERS TO FORM 
POLYMERIC MATERALS 
BACKGROUND OF THE INVENTION 
This is a continuation of application Ser. No. 08/467,693, 
filed Jun. 6, 1995, now U.S. Pat. No. 5,834,274, which is a 
divisional of prior application Ser. No. 08/024,657 filed on 
Mar. 1, 1993, now U.S. Pat. No. 5,573.934, which is a 
continuation-in-part of U.S. Ser. No. 07/958,870, filed Oct. 
7, 1992, now U.S. Pat. No. 5,529,914, which is a 
continuation-in-part of U.S. Ser. No. 07/870,540, filed Apr. 
20, 1992 now abandoned. This application is also a 
continuation-in-part of Ser. No. 08/475,175, filed Jun. 7, 
1995, now U.S. Pat. No. 5,846,530, which is a divisional of 
U.S. Ser. No. 08/232,054, filed Apr. 28, 1994, now U.S. Pat. 
No. 5,837.747. 
FIELD OF THE INVENTION 
The present invention relates to methods for coating 
and/or encapsulating Surfaces and three-dimensional objects 
with croSS-linked networks of water-Soluble polymers. 
Microencapsulation technology holds promise in many 
areas of medicine. For example, Some important applica 
tions are encapsulation of cells for the treatment of diabetes 
(Lim, F., Sun, A. M. “Microencapsulated islets as bioartifi 
cial endocrine pancreas”, (1980) Science 210, 908-910), 
encapsulation of hemoglobin for red blood cell Substitutes, 
and controlled release of drugs. However, using the prior art 
methods, the materials to be encapsulated are often exposed 
to processing conditions, including heat, organic Solvents 
and non-physiological pHs, which can kill or functionally 
impair cells or denature proteins, resulting in loSS of bio 
logical activity. Further, even if cells Survive the processing 
conditions, the Stringent requirements of biocompatibility, 
chemical Stability, immunoprotection and resistance to cel 
lular overgrowth, of the encapsulating materials restrict the 
applicability of prior art methods. 
For example, the encapsulating method based on ionic 
crosslinking of alginate (a polyanion) with polylysine or 
polyornithine (polycation) (Goosen, et al., (1985) Biotech 
nology and Bioengineering, 27:146) offers relatively mild 
encapsulating conditions, but the long-term mechanical and 
chemical Stability of Such ionically crosslinked polymers 
remains doubtful. Moreover, these polymers when 
implanted in Vivo are Susceptible to cellular Overgrowth 
(McMahon, et al., (1990) J. Nat. Cancer Inst., 82(22), 
1761-1765) which over time restricts the permeability of the 
microcapsule to nutrients, metabolites and transport proteins 
from the Surroundings. This has lead to Starvation and death 
of encapsulated islets of Langerhorns (O'Shea, G. M. et al. 
(1986) Diabetes, 35:943–946). 
Thus, there remains a need for a relatively mild cell 
encapsulation method which offers control over properties 
of the encapsulating polymer and yields membranes in the 
presence of cells which are permselective, chemically stable, 
and very highly biocompatible. A similar need exists for the 
encapsulation of biological materials other than cells and 
tissues, as well as materials contacting biological materials. 
Materials are considered biocompatible if the material 
elicits either a reduced specific humoral or cellular immune 
response or does not elicit a nonspecific foreign body 
response that prevents the material from performing the 
intended function, and if the material is not toxic upon 
ingestion or implantation. The material must also not elicit 












Gels made of polymers which Swell in water to form a 
hydrogel, Such as poly(hydroxyethyl methacrylate) (poly 
(HEMA)), water-insoluble polyacrylates, and agarose, have 
been shown to be useful for encapsulating islets and other 
animal tissue (Iwata, et al., (1989) Diabetes, 38:224-225; 
Lamberti, et al., (1984) Appl. Biochem. Biotech., 10, 
101-105 (1984). However, these gels have undesirable 
mechanical properties. Agarose forms a weak gel, and the 
polyacrylates must be precipitated from organic Solvents, 
which are potentially cytotoxic. Dupuy, et al. (1988) have 
reported the microencapsulation of islets by polymerization 
of acrylamide to form polyacrylamide gels. However, the 
polymerization process requires the presence of toxic mono 
merS Such as acrylamide and croSS-linkers, and, if allowed to 
proceed rapidly to completion, generates local heat. 
Microcapsules formed by the coacervation of alginate and 
poly(L-lysine) have been shown to be immunoprotective, 
for example, as described by O'Shea, et al., 1986. However, 
a Severe fibrous Overgrowth of these microcapsules was 
observed following implantation (McMahon, et al. 1990; 
O'Shea, et al., 1986). The use of poly(ethylene oxide) (PEO) 
to increase biocompatibility is well documented in literature. 
The biocompatibility of alginpoly(L-lysine) microcapsules 
has been reported to be Significantly enhanced by incorpo 
rating a graft copolymer of PLL and PEO on the microcap 
Sule surface (Sawhney, et al., “Poly(ethylene oxide)-Graft 
Poly(L-Lysine) Copolymers to Enhance the 
Biocompatibility of Poly(L-Lysine)-Alginate Microcapsule 
Membranes,” (1991) Biomaterials, 13, 863–870). 
The PEO chain is highly water soluble and highly flexible. 
PEO chains have an extremely high motility in water and are 
essentially non-ionic instructure. Immobilization of PEO on 
a Surface has been largely carried out by the Synthesis of 
graft copolymers having PEO Side chains (Sawhney, et al., 
Miyama, et al., 1988; Nagoaka, et al.). This process involves 
the custom Synthesis of monomers and polymers for each 
application. The use of graft copolymers, however, Still does 
not guarantee that the Surface “seen by a macromolecule 
consists entirely of PEO. 
Electron beam cross-linking has been used to Synthesize 
PEO hydrogels, which have been reported to be non 
thrombogenic by Sun, et al., (1987) Polymer Prepr., 
28:292–294; Dennison, K. A., (1986) Ph.D. Thesis. Massa 
chusetts Institute of Technology. However, use of an elec 
tron beam precludes including with the polymer any living 
tissue Since the radiation is cytotoxic. Also, the networks 
produced by this method are difficult to characterize due to 
the non-specific cross-linking induced by the electron beam. 
Photopolymerization of PEG diacrylates in the presence 
of short wavelength ultraViolet light initiation has been used 
to entrap yeast cells for fermentation and chemical conver 
sion (Kimura, et al. (1981), “Some properties of immobi 
lized glycolysis System of yeast in fermentative phosphory 
lation of nucleotides,” Eur: J. Appl. Microbio. Biotechnol., 
11:78–80; Omata et al., (1981), “Steroselectic hydrolysis of 
dl-methyl Succinate by gel-entrapped Rhodotorula minuta 
uZr. texensis cells in organic Solvent, Eur: J. Appl. Micro 
bial Biotechnol, 11:199-204; Okada, T., et al., “Application 
of Entrapped Growing Yeast Cells to Peptide Secretion 
System.” Appl. Microbiol. Biotechnol., Vol. 26, pp. 112-116 
(1987). Other methods for encapsulation of cells within 
materials photopolymerizable with Short wavelength ultra 
violet radiation have been used with microbial cells 
(Kimura, et al., 1981; Omata, et al., 981; Okada, et al., 1987; 
Tanaka, et al., 1977; Omata, et al., 1979a; Omata, et al., 
1979b, Chun, et al., 1981, Fukui, et al., 1976, Fukui, et al., 
1984). However, yeast cells and some microbial cells are 
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much hardier and resistant to adverse environments, 
elevated temperatures, and short wavelength ultraViolet 
radiation than mammalian cells and human tissues. 
There are Several problems with these methods, including 
the use of methods and/or materials which are thrombogenic 
or unstable in Vivo, or require polymerization conditions 
which tend to destroy living mammalian tissue or biologi 
cally active molecules, for example, short wavelength ultra 
Violet radiation. In order to encapsulate living tissue for 
implantation in a human or other mammalian Subject, the 
polymerization conditions must not destroy the living tissue, 
and the resulting polymer-coated cells must be biocompat 
ible. 
There is also a need to encapsulate materials within a very 
thin layer of material that is permeable to nutrients and 
gases, yet strong and non-immunogenic. For example, for 
transplantation of islets of Langerhans, the islets, which 
have a diameter of 100 to 200 microns, have in the past been 
encapsulated within microSpheres that have a diameter of 
400 to 1000 microns. This large diameter can result in 
slowed diffusion of nutritional molecules and large trans 
plantation volumes. 
In Summary, there is a need for materials, and methods of 
use thereof, which can be used to encapsulate cells and 
tissueS or biologically active molecules which are 
biocompatible, do not elicit specific or non-specific immune 
responses, and which can be polymerized in contact with 
living cells or tissue without injuring or killing the cells, 
within a very short time frame, and in a very thin layer. An 
important aspect of the use of these materials in Vivo is that 
they must be polymerizable within the time of a short 
Surgical procedure or before the material to be encapsulated 
disperses, is damaged or dies. 
It is therefore an object of the present invention to provide 
a polymeric material that can be polymerized in contact with 
living cells and tissues, and in a very short time period. 
It is a further object of the present invention to provide a 
polymeric material which is biocompatible and resistant to 
degradation for a specific time period. 
It is a still further object of the present invention to 
provide a polymeric material which is permeable to nutrients 
and gases yet can protect cells and tissues from in vivo 
attack by other cells. 
SUMMARY OF THE INVENTION 
Disclosed herein is a method for polymerization of mac 
romers using visible or long wavelength ultraViolet light (lw 
uV light, 320 nm or greater) to encapsulate or coat either 
directly or indirectly living tissue with polymeric coatings 
which conform to the Surfaces of cells, tissueS or carriers 
thereof under rapid and mild polymerization conditions, 
Polymers are formed from non-toxic pre-polymers, referred 
to herein as macromers, that are water-Soluble or Substan 
tially water soluble and too large to diffuse into the cells to 
be coated. Examples of macromers include highly biocom 
patible PEG hydrogels, which can be rapidly formed in the 
presence or absence of oxygen, without use of toxic poly 
merization initiators, at room or physiological temperatures, 
and at physiological pH. Polymerization may be initiated 
using non-toxic dyes Such as methylene blue or eosin Y, 
which are photopolymerizable with visible or lw uV light. 
Other dyes that diffuse into the cells but are nontoxic, such 
as ethyl eosin, may also be used. The process is non 
cytotoxic because little light is absorbed by cells in the 
absence of the proper chromophore. Cells are largely trans 











radiation, which is Strongly absorbed by cellular proteins 
and nucleic acids and can be cytotoxic. Low levels of 
irradiation (5-500 mW) are usually enough to induce poly 
merization in a time period of between milliseconds to a few 
Seconds for most macromers. A Second reason for the lack 
of cytotoxicity is that the polymerizable Species does not 
diffuse into cells. 
The resulting polymers can act as Semipermeable 
membranes, as adhesives as tissue Supports, as plugs, as 
barriers to prevent the interaction of one cell tissue with 
another cell or tissue, and as carriers for bioactive Species. 
A wide variety of Surfaces, with different geometries, can be 
coated with a three dimensionally croSS-linked network of 
these polymeric materials. The polymers can be formed into 
a matrix for delivery of biologically active materials, includ 
ing proteins, polysaccharides, organic compounds with drug 
activity, and nucleic acids. 
In one preferred embodiment, the polymer is used to form 
a layer on the inside of the lumen of a blood vessel, either 
for Structural Support, prevention of thrombosis and inflam 
matory reactions at the lumen Surface, and/or delivery of 
therapeutic agents to the blood vessel. In another preferred 
embodiment, the polymer is used to create a Semipermeable 
barrier around cells Such as islets of Langerhans to protect 
the cell by preventing the passage of immunoglobulins 
molecules or cells, while allowing free transfer of nutrients, 
gases and Small cell products. Such treated islets may be 
useful in treating diseases which result from deficiencies in 
metabolic processing, or diseases like diabetes which arise 
from insufficient concentrations of bioregulator molecules. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a reaction scheme for ethyl eosin initiated 
polymerization. 
FIG. 2 is a Schematic of dye-initiated polymerization of a 
PEG layer around crosslinked alginate microSpheres. 
FIG. 3 is a schematic of photopolymerization of a PEG 
coating on alginate-poly(L-lysine) microspheres Suspended 
in mineral oil. 
FIG. 4 is a Schematic representation of coextrusion appa 
ratus used for microencapsulation using laser polymeriza 
tion 
FIG. 5 is a graph of the number of cells versus gel 
composition, for the unattached cells obtained from lavage 
of the peritoneal cavity in mice with different PEO overcoat 
gel compositions: a-18.5 k; b-10% 0.5 k, 90%. 18.5 k; 
c-50%. 18.5 k, 50% 0.4 k; d. 10% 0.4 k, 90% 35 k; 
e-50% 0.4k, 50% 35 k; and f -alginate-poly(L-lysine) 
control. 
FIG. 6 is a graph of the % protein released versus time in 
minutes, for diffusion of bovine serum albumin (open 
Squares), human IgG (triangles) and human fibrinogen 
(closed squares) through a PEO 18.5 K-tetraacrylate gel. 
FIG. 7 is a graph of the % diffusion of bovine serum 
albumin over time in minutes through PEO 400 diacrylate 
(open Squares) and PEG 18.5 K-tetracrylate (triangles) gels. 
FIG. 8 is a graph of the length in mm of gel produced by 
argon ion laser induced polymerization versus log (time) 
(ms) of trimethylolpropane using an amine and ethyl eosin 
initiation System. 
FIGS. 9A-C are creep curves for PEG diacrylate and 
tetraacrylate gels, test and recovery loads are given below 
the abscissa: A-1 k; B-6 K; and C-18.5 K PEG gels. 
DETAILED DESCRIPTION OF THE 
INVENTION 
AS described herein, biocompatible polymeric materials 
are formed for use in juxtaposition with biologically active 
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materials or cells and tissue, by free radical polymerization 
of biocompatible water Soluble macromers including at least 
two polymerizable Substituents. These polymeric coating 
materials can be either homopolymers, copolymers or block 
copolymers. AS used herein, a polymer is a unit formed 
having a degree of polymerization greater than 10, and an 
oligomer has a degree of polymerization of between 2 and 
10, degree of polymerization meaning the number of repeat 
units in the Structure, e.g., d.p.=3 refers to a trimer. Poly 
merization of a component that has at least two polymeriZ 
able Substituents is equal to gelation; the polymerization 
proceeds to form a three-dimensional, croSS-linked gel. 
Pre-polymers (Macromers) useful for Making Gels. 
The general criteria for pre-polymers (referred to herein 
as macromers) that can be polymerized in contact with 
biological materials or cells are that: they are water-Soluble 
or substantially water soluble, they can be further polymer 
ized or crosslinked by free radical polymerization, they are 
non-toxic and they are too large to diffuse into cells, i.e., 
greater than 200 molecular weight. Substantially water 
soluble is defined herein as being soluble in a mixture of 
water and organic Solvent(s), where water makes up the 
majority of the mixture of Solvents. 
AS used herein, the macromers must be photopolymeriz 
able with light alone or in the presence of an initiator and/or 
catalyst, Such as a free radical photoinitiator, wherein the 
light is in the Visible or long wavelength ultraViolet range, 
that is, greater than or equal to 320 nm. Other reactive 
conditions may be Suitable to initiate free radical polymer 
ization if they do not adversely affect the viability of the 
living tissue to be encapsulated. The macromers must also 
not generate products or heat levels that are toxic to living 
tissue during polymerization. The catalyst or free radical 
initiator must also not be toxic under the conditions of use. 
A wide variety of substantially water soluble polymers 
exist, Some of which are illustrated Schematically below. ( ) 
represents a Substantially water Soluble region of the 
polymer, and (=) represents a free radical polymerizable 













Examples of A include PEG diacrylate, from a PEG diol; 
of B include PEG triacrylate, formed from a PEG triol; of C 
include PEG-cyclodextrin tetraacrylate, formed by grafting 
PEG to a cyclodextrin central ring, and further acrylating, of 
D include PEG tetraacrylate, formed by grafting two PEG 
diols to a bis epoxide and further acrylating, of E include 
hyaluronic acid methacrylate, formed by acrylating many 
sites on a hyaluronic acid chain; of F include PEG 
hyaluronic acid-multiacrylate, formed by grafting PEG to 
hyaluronic acid and further acrylating; of G include PEG 
unsaturated diacid ester formed by esterifying a PEG diol 
with an unsaturated diacid. 
Polysaccharides include, for example, alginate, hyalu 
ronic acid, chondroitin Sulfate, dextran, dextran Sulfate, 
heparin, heparin Sulfate, heparan Sulfate, chitosan, gellan 
gum, Xanthan gum, guar gum, and K-carrageenan. Proteins, 
for example, include gelatin, collagen, elastin and albumin, 
whether produced from natural or recombinant Sources. 
Photopolymerizable substituens preferably include 
acrylates, diacrylates, oligoacrylates, dimethacrylates, or 
oligomethoacrylates, and other biologically acceptable pho 
topolymerizable groups. 
Synthetic Polymeric Macromers. 
The water-soluble macromer may be derived from water 
Soluble polymers including, but not limited to, poly(ethylene 
oxide) (PEO), poly(ethylene glycol) (PEG), poly(vinyl 
alcohol) (PVA) poly(vinylpyrrollidone) (PVP), poly 
(ethyl oxazoline) (PEOX) poly a mino acids, 
pseudopolyamino acids, and polyethyloxazoline, as well as 
copolymers of these with each other or other water soluble 
polymers or water insoluble polymers, provided that the 
conjugate is water Soluble. An example of a water Soluble 
conjugate is a block copolymer of polyethylene glycol and 
polypropylene oxide, commercially available as a Plu 
ronicTM Surfactant. 
Polysaccharide Macromers 
Polysaccharides Such as alginate, hyaluronic acid, chon 
droitin Sulfate, dextran, dextran Sulfate, heparin, heparin 
Sulfate, heparan Sulfate, chitosan, gellan gum, Xanthan gum, 
guar gum, water Soluble cellulose derivatives, and 
carrageenan, which are linked by reaction with hydroxyls or 
amines on the polysaccharides can also be used to form the 
macromer Solution. 
Protein Macromers 
Proteins Such as gelatin, collagen, elastin, Zein, and 
albumin, whether produced from natural or recombinant 
Sources, which are made free-radical polymerization by the 
addition of carbon-carbon double or triple bond-containing 
moieties, including acrylate, diacrylate, methacrylate, 
ethacrylate, 2-phenyl acrylate, 2-chloro acrylate, 2-bromo 
acrylate, itaconate, oliogoacrylate, dimethacrylate, 
oligomethacrylate, acrylamide, methacrylamide, Styrene 
groups, and other biologically acceptable photopolymeriZ 
able groups, can also be used to form the macromer Solution. 
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Dye-sensitized Polymerization 
Dye-Sensitized polymerization is well known in the 
chemical literature. For example, light from an argon ion 
laser (514 nm), in the presence of an Xanthin dye and an 
electron donor, Such as triethanolamine, to catalyze 
initiation, Serves to induce a free radical polymerization of 
the acrylic groups in a reaction mixture (Neckers, et al., 
(1989) Polym. Materials Sci. Eng., 60:15; Fouassier, et al., 
(1991) Makromol. Chem., 192:245-260). After absorbing 
the laser light, the dye is excited to a triplet State. The triplet 
State reacts with a tertiary amine Such as the triethanolamine, 
producing a free radical which initiates the polymerization 
reaction. Polymerization is extremely rapid and is dependent 
on the functionality of the macromer and its concentration, 
light intensity, and the concentration of dye and amine. 
Photoinitiating Dyes 
Any dye can be used which absorbs light having a 
frequency between 320 nm and 900 nm, can form free 
radicals, is at least partally water Soluble, and is non-toxic to 
the biological material at the concentration used for poly 
merization. There are a large number of ohotoSensitive dyes 
that can be used to optically initiate polymerization, Such as 
ethyl eosin, eosin Y, fluorescein, 2,2-dimethoxy-2-phenyl 
acetophe none, 2-methoxy, 2-phenylace top he none, 
camphorquinone, rose bengal, methylene blue, erythrosin, 
phloxime, thionine, riboflavin, methylene green, acridine 
orange, Xanthine dye, and thioxanthine dyes. 
The preferred initiator dye is ethyle eosin due to its 
spectral properties in aqueous Solution (absorption max=528 
nm, extinction coefficient=1.1x10 M'cm, fluorescence 
max=547 nm, quantum yield=0.59). A reaction scheme 
using ethyl eosin is shown in FIG. 1 as an example. The dye 
bleaches after illumination and reaction with amine into a 
colorless product, allowing further beam penetration into the 
reaction System. 
Cocatalyst. 
The cacatalysts useful with the photoinitiating dyes are 
nitrogen based compounds capable of Stimulating the free 
radical reaction. Primary, Secondary, tertiary or quaternary 
amines are Suitable cocatalysts, as are any nitrogen atom 
containing electron-rich molecules. Cocatalysts include, but 
are not limited to, triethanolamine, triethylamine, 
ethanolamine, N-methyl diethanolamine, N,N-dimethyl 
benzylamine, dibenzyl amine, N-benzyl ethanolamine, 
N-isopropyl benzylamine, tetramethyl ethylenediamine, 
potassium perSulfate, tetramethyl ethylenediamine, lysine, 
ornithine, histidine and arginine. 
Examples of the dye/photoinitiator System includes ethyl 
eosin with an amine, eosin Y with an amine, 2,2-dimethoxy 
2-phen oxyace top he none, 2-methoxy-2- 
phenoxyacetophenone, camphorquinone with an amine, and 
rose bengal with an amine. 
In Some cases, the dye may absorb light and initiate 
polymerization, without any additional initiator Such as the 
amine. In these cases, only the dye and the macromer need 
be present to initiate polymerization upon exposure to light. 
The generation of free radicals is terminated when the laser 
light is removed. Some photoinitiators, Such as 2,2- 
dimethoxy-2-phenylacetophenone, do not require any aux 
iliary amine to induce photopolymerization; in these cases, 
only the presence of dye, macromer, and appropriate wave 
length light is required. 
Means for Polymerization. 
Photopolymerization. 
Preferred light Sources include various lamps and lasers 
Such as those described in the following examples, which 
have a wavelength of about 320-800 nm, most preferably 











This light can be provided by any appropriate Source able 
to generate the desired radiation, Such as a mercury lamp, 
longwave UV lamp, He-Ne laser, or an argon ion laser, or 
through the use of fiber optics. 
Other Means for Polymerization. 
Means other than light can be used for polymerization. 
Examples include initiation by thermal initiators, which 
form free radicals at moderate temperatures, Such as benzoyl 
peroxide, with or without triethanolamine, potassium 
perSulfate, with or without tetramethylethylenediamine, and 
ammonium perSulfate with Sodium bisulfite. 
Incorporation of Biologically Active Materials. 
The water Soluble macromers can be polymerized around 
biologically active molecules to form a delivery System for 
the molecules or polymerized around cells, tissues, Sub 
cellular organelles or other Sub-cellular components to 
encapsulate the, biological material. The water Soluble mac 
romers can also be polymerized to incorporate biologically 
active molecules to impart additional properties to the 
polymer, Such as resistance to bacterial growth or decrease 
in inflammatory response, as well as to encapsulate tissues. 
A wide variety of biologically active material can be encap 
Sulated or in corporated, including proteins, peptides, 
polysaccharides, organic or inorganic drugs, nucleic acids, 
Sugars, cells, and tissues. 
Examples of cells which can be encapsulated include 
primary cultures as well as established cell lines, including 
transformed cells. These include but are not limited to 
pancreatic islet cells, human foreskin fibroblasts, Chinese 
hamster ovary cells, beta cell insulomas, lymphoblastic 
leukemia cells, mouse 3T3 fibroblasts, dopamine Secreting 
Ventral mesencephalon cells, neuroblastoid cells, adrenal 
medulla cells, and T-cells. AS can be seen from this partial 
list, cells of all types, including dermal, neural, blood, organ, 
muscle, glandular, reproductive, and immune System cells, 
as well as Species of origin, can be encapsulated Successfully 
by this method. Examples of proteins which can be encap 
Sulated include hemoglobin, enzymes Such as adenosine 
deaminase, enzyme Systems, blood clotting factors, inhibi 
tors or clot dissolving agents Such as Streptokinase and tissue 
plasminogen activator, antigens for immunization, and 
hormones, polysaccharides Such as heparin, oligonucle 
otides Such as antisense, bacteria and other microbial 
organisms, including viruses, Vitamins, cofactors, and ret 
roviruses for gene therapy can be encapsulated by these 
techniques. 
The biological material can be first enclosed in a structure 
such as a polysaccharide gel. (Lim, U.S. Pat. No. 4.352,883; 
Lim, U.S. Pat. No. 4,391,909; Lim, U.S. Pat. No. 4,409,331; 
Tsang, et al., U.S. Pat. No. 4,663.286; Goosen et al., U.S. 
Pat. No. 4,673,556; Goosen et al., U.S. Pat. No. 4,689,293; 
Goosen et al., U.S. Pat. No. 4,806,355; Rha et al., U.S. Pat. 
No. 4,744933; Rha et al., U.S. Pat. No. 4,749,620, incor 
porated herein by reference.) Such gels can provide addi 
tional Structural protection to the material, as well as a 
Secondary level of perm-Selectivity. 
Polymerization. 
The macromers are preferably mixed with initiator, 
applied to the material or site where they are to be 
polymerized, and exposed to initiating agent, Such as light or 
heat. 
In a preferred method, a photo-initiating System is added 
to an aqueous Solution of a photopolymerizable macromer to 
from an aqueous mixture; the biologically active material is 
added; and the aqueous Solution irradiated with light. The 
macromer is preferably formed of a water Soluble polymer 
with photopolymerizable Substituents. Light absorption by 
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the dye/initiator system results in the formation of free 
radicals which initiate polymerization. 
In a Second preferred method, macromer is coated on the 
Surface of a three-dimensional object which may be of 
biological origin or a Synthetic Substrate for implantation in 
an animal. Water-Soluble macromer is mixed with a photo 
initiating System to form an aqueous mixture; the mixture is 
applied to a Surface to be coated to form a coated Surface; 
and the coated Surface is irradiated with light to initiate 
macromer polymerization. 
In a variation of this embodiment, the synthetic substrate 
can be a hydrophilic microSphere, microcapsule or bead. 
The hydrophilic microspheres are mixed with a water 
Soluble macromer Solution in combination with a photoini 
tiator System to form an aqueous mixture; the microSpheres 
are Suspended with agitation with macromer in oil to form 
an oil Suspension, and the microSpheres are irradiated with 
light. 
In another particularly preferred embodiment, a photo 
Sensitive dye is absorbed to a tissue Surface which is to be 
treated, the non-absorbed dye is diluted out or rinsed off the 
tissue, the macromer Solution is applied to the dye-coupled 
Surface, and polymerization initiated, to result in interfacial 
polymerization. 
Polymerization can be effected by at least five different 
methods utilizing bulk polymerization or interfacial poly 
merization. These embodiments are further described below 
with respect to Specific applications of the materials and 
processes for polymerization thereof. 
Bulk Polymerization. 
In bulk polymerization the material to be coated is placed 
in contact with a Solution of macromer, photoinitiator and 
optionally cocatalyst, and then polymerization induced, for 
example, by exposure to radiation. Three examples of bulk 
polymerization follow: 
Bulk Suspension Polymerization Method for Encapsulation 
of Material. 
Biological material to be encapsulated is mixed with an 
aqueous macromer Solution, including macromer, cocatalyst 
and optionally an accelerator, and initiator. Small globular 
geometric Structures Such as Spheres, ovoids, or oblongs are 
formed, preferably either by coextrusion of the aqueous 
Solution with air or with a non-miscible Substance Such as 
oil, preferably mineral oil, or by agitation of the aqueous 
phase in contact with a non-miscible phase Such as an oil 
phase to form Small droplets. The macromer in the globules 
is then polymerized by exposure to radiation. Because the 
macromer and initiator are confined to the globules, the 
Structure resulting from polymerization is a capsule in which 
the biological material is enclosed. This is a "Suspension 
polymerization' whereby the entire aqueous portion of the 
globule polymerizes to form a thick membrane around the 
cellular material. 
Microcapsule Suspension Polymerization Method. 
In a variation of the bulk Suspension method, microen 
capsulated material is used as a core about which the 
macromer is polymerized in a Suspension polymerization 
reaction. The biological material is first encapsulated within 
a microsphere, microcapsule, or microparticle (referred to 
herein collectively as microcapsules), for example, in algi 
nate microcapsules. The microcapsules are then mixed with 
the macromer Solution and initiator, and the macromer 
Solution polymerized. 
This method is particularly suitable for use with PEG 
macromers, taking advantage of the extreme hydrophilicity 
of PEG macromers, and is especially well adapted for use 












lysine). The microsphere is swollen in water. When a 
macromer Solution containing catalyst and/or initiator or 
accelerator is forced to phase Separate in a hydrophobic 
medium, Such as mineral oil, the PEG macromer Solution 
prefers to Stay on the hydrophilic Surface of the alginate 
microcapsule. When this suspension is irradiated, the PEG 
macromer undergoes polymerization and gelation, forming a 
thin layer of polymeric, water insoluble gel around the 
microSphere. 
This technique preferably involves coextrusion of the 
microcapsule in a Solution of macromer and initiator, the 
Solution being in contact with air or a liquid which is 
non-miscible with water, to form droplets which fall into a 
Solution Such as mineral oil in which the droplets are not 
miscible. The non-miscible liquid is chosen for its ability to 
maintain droplet formation. Additionally, if the membrane 
encapsulated material is to be injected or implanted in an 
animal, any residue should be non-toxic and non 
immunogenic. Mineral oil is a preferred non-miscible liquid. 
Once the droplets have contacted the non-miscible liquid, 
they are polymerized. 
This coextrusion technique results in a crosslinked poly 
mer coat of greater than 50 microns thickness. Alternatively, 
the microcapsules may be Suspended in a Solution of mac 
romer and initiator which is agitated in contact with a 
non-miscible phase Such as an oil phase. The resulting 
emulsion is polymerized to form a polymer coat, also of 
greater than 50 microns thickness, around the microcap 
Sules. 
Bulk Polymerization Method for Tissue Adhesion. 
The polymeric material can also be used to adhere tissue. 
A water Soluble polymerizable macromer in combination 
with a photoinitiator is applied to a tissue Surface to which 
tissue adhesion is desired; the tissue Surface is contacted 
with the tissue with which adhesion is desired, forming a 
tissue junction; and the tissue junction is irradiated with light 
until the macromers are polymerized. In the preferred 
embodiment, this is accomplished in Seconds up to minutes, 
most preferably Seconds. 
In the preferred embodiment, the macromer mixture is an 
acqueous solution, such as that of PEG 400 diacrylate or PEG 
18.5 K tetraacrylate. When this solution contacts tissue 
which has a moist layer of mucous or fluid covering it, it 
intermixes with the moisture on the tissue. The mucous layer 
on tissue includes water Soluble polysaccharides which 
intimately contact cellular Surfaces. These, in turn, are rich 
in glycoproteins and proteoglycans. Thus, physical inter 
mixing and forces of Surface interlocking due to penetration 
into crevices, are Some of the forces responsible for the 
adhesion of the PEG gel to a tissue Surface Subsequent to 
crosslinking. 
Specific applications for Such adhesives may include 
blood vessel anastomosis, Soft tissue reconnection, drainable 
burn dressings, and retinal reattachment. 
Bulk Polymerization to form Tissue Barriers 
If the PEG gel is polymerized away from tissue, it then 
presents a very non-adhesive Surface to cells and tissue in 
general, due to the highly hydrophilic nature of the material. 
This feature can be exploited to form barriers upon tissues 
to prevent attachment of cells to the coated tissue. Examples 
of this application include the formation of barriers upon 
islets of Langerhans or upon the lumen of blood vessels to 
prevent thrombosis or vasospasm or vessel collapse; 
whether by bulk polymerization (with the polymerization 
initiator mixed in with the macromer) or by interfacial 
polymerization (with the initiator absorbed to the surface). 
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Interfacial Polymerization. 
For interfacial polymerization, the free radical initiator is 
adsorbed to the Surface of the material to be coated, non 
adsorbed initiator is diluted out or rinsed off, using a rinsing 
Solution or by application of the macromer Solution, and the 
macromer Solution, optionally containing a cocatalyst, is 
applied to the material, which is then polymerized. Two 
examples of interfacial polymerization follow: 
Microcapsule Interfacial Polymerization Method. 
Biological material can be encapsulated as described 
above with reference to Suspension polymerization, but 
utilizing interfacial polymerization to form the membrane on 
the Surface of the biological material or microcapsule. This 
involves coating the biological material or microcapsule 
with photoinitiator, Suspending the biological material or 
microcapsules in the macromer Solution, and immediately 
polymerizing, for example, by irradiating. A thin polymer 
coat, of less than 50 microns thickness, is formed around the 
biological materials or the microcapsule, because the pho 
toinitiator is present only at the microcapsule Surface and is 
given insufficient time to diffuse far into the macromer 
Solution. 
In most cases, initiator, Such as a dye, will penetrate into 
the interior of the biological material or the microcapsule, as 
well as adsorbing to the Surface. When macromer Solution, 
optionally containing a cocatalyst Such as triethanolamine, is 
applied to the Surface and exposed to an initatiating agent 
Such as laser light, all the essential components of the 
reaction are present only at and just inside the interface of 
the biological material or microcapsule and macromer Solu 
tion. Hence, polymerization and gelation (if multifunctional 
macromer is used), which typically occurs within about 100 
mSec, initially takes place only at the interface, just beneath 
it, and just beyond it. If left for longer periods of time, 
initiator Starts diffusing from the inner core of the micro 
Sphere into the Solution; Similarly, macromerS Start diffusing 
inside the core and a thicker layer of polymer is formed. 
Direct Interfacial Polymerization Method. 
Interfacial polymerization to form a membrane directly on 
the Surface of tissues. Tissue is directly coated with initiator, 
exceSS initiator is removed, macromer Solution is applied to 
the tissue and polymerized. 
Control of Polymer Permeability. 
The permeability of the coating is determined in part by 
the molecular weight and crosslinking of the polymer. For 
example, in the case of short PEG chains between 
crosslinks, the “pore” produced in the network will have 
relatively rigid boundaries and will be relatively small so 
that a macromolecule attempting to diffuse through this gel 
will be predominantly restricted by a sieving effect. If the 
chain length between croSSlinkS-is long, the chain can fold 
and move around with a high motility So that diffusing 
macromolecules will encounter a free Volume exclusion 
effect as well as a Sieving effect. 
Due to these two contrasting effects a Straightforward 
relation between molecular weight cutoff for diffusion and 
the molecular weight of the Starting oligomer is not com 
pletely definable. Yet, a desired release profile for a particu 
lar protein or a drug Such as a peptide can be accomplished 
by adjusting the crosslink density and length of PEG Seg 
ments. Correspondingly, a desired protein permeability pro 
file can be designed to permit the diffusion of nutrients, 
oxygen, carbon dioxide, waste products, hormones, growth 
factors, transport proteins, and Secreted cellularly Synthe 
sized products Such as proteins, while restricting the diffu 
Sion of immune modulatorS Such as antibodies and comple 











to protect transplanted cells or tissue. The three dimensional 
crosslinked covalently bonded polymeric network is chemi 
cally stable for long-term in Vivo applications. 
For purposes of encapsulating cells and tissue in a manner 
which prevents the passage of antibodies acroSS the mem 
brane but allows passage of nutrients essential for cellular 
metabolism, the preferred Starting macromer Size is in the 
range of between 10,000 D and 18,500 D, with the most 
preferred being around 18,500 D. Smaller macromers result 
in polymer membranes of a higher density with Smaller 
pores. 
Thickness and Conformation of Polvmer Layer. 
Membrane thickness affects a variety of parameters, 
including perm-Selectivity, rigidity, and Size of the mem 
brane. ThickneSS can be varied by Selection of the reaction 
components and/or the reaction conditions. For example, the 
macromer concentration can be varied from a few percent to 
100%, depending upon the macromer. Similarly, more 
intense illuminations and longer illuminations will yield 
thicker films than less intense or shorter illuminations will. 
Accelerators may also be added in varying concentration to 
control thickness. For example, N-Vinylpyrrolidinone may 
be added as an accelerator, with higher concentrations 
yielding thicker layers than lower concentrations, all other 
conditions being equal. As an example, 
N-Vinylpyrrolidinone concentrations can range from 0 to 
O.5%. 
In the interfacial polymerization method, the duration of 
the polymerization can be varied to adjust the thickness of 
the polymer membrane formed. This correlation between 
membrane thickneSS and duration of irradiation occurs 
because the photoinitiator diffuses at a steady rate, with 
diffusion being a continuously occurring process. Thus, the 
longer the duration of irradiation, the more photoinitiator 
will initiate polymerization in the macromer mix, the more 
macromer will polymerize, and the thicker the resulting 
membrane. Additional factors which affect membrane thick 
neSS are the number of reactive groups per macromer and the 
concentration of accelerators in the macromer Solution. This 
technique allows the creation of very thin membranes 
because the photoinitiator is first present in a very thin layer 
at the Surface of the biological material, and polymerization 
only occurs where the photoinitiator is present. 
In the Suspension polymerization method, a Somewhat 
thicker membrane is formed than with the interfacial poly 
merization method, Since in the Suspension method poly 
merization occurs throughout the macromer Solution. The 
thickness of membranes formed by the Suspension method is 
determined in part by the Viscosity of the macromer Solution, 
the concentration of the macromer in that Solution, the fluid 
mechanical environment of the Suspension and Surface 
active agents in the Suspension. These membranes vary in 
thickness from between 50 and 300 microns. 
Non-Biological Surfaces. 
The macromer Solution and initiator can also be applied to 
a non-biological Surface intended to be placed in contact 
with a biological environment. Such Surfaces include, for 
example, Vascular grafts, contact lenses, intraocular lenses, 
ultrafiltration membranes, and containers for biological 
materials. 
It is usually difficult to get good adhesion between poly 
mers of greatly different physicochemical properties. The 
concept of a Surface physical interpenetrating network was 
presented by Desai and Hubbel (N. P. Desai et al. (1992)). 
This approach to incorporating into the Surface of one 
polymer a complete coating of a polymer of considerably 
different properties involved swelling the surface of the 
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polymer to be modified (base polymer) in a mutual Solvent, 
or a Swelling Solvent, for the base polymer and for the 
polymer to be incorporated (penetrant polymer). The pen 
etrant polymer diffused into the Surface of the base polymer. 
This interface was Stabilized by rapidly precipitating or 
deSWelling the Surface by placing the base polymer in a 
nonsolvent bath. This resulted in entanglement of the pen 
etrant polymer within the matrix of the base polymer at its 
Surface in a structure that was called a Surface physical 
interpenetrating network. 
This approach can be improved upon by photopolymer 
izing the penetrant polymer upon the Surface of the base 
polymer in the Swollen State. This results in much enhanced 
Stability over that of the previous approach and in the 
enhancement of biological responses to these materials. The 
penetrant may be chemically modified to be a prepolymer 
macromer, i.e. capable of being polymerized itself. This 
polymerization can be initiated thermally or by exposure to 
Visible, ultraViolet, infrared, gamma ray, or electron beam 
irradiation, or to plasma conditions. In the case of the 
relatively nonspecific gamma ray or electron beam radiation 
reaction, chemical incorporation of particularly reactive 
Sites may not be necessary. 
Polyethylene glycol (PEG) is a particularly useful pen 
etrant polymer for biomedical applications where the lack of 
cell adhesion is desired. The previous work had demon 
Strated an optimal performance at a molecular weight of 
18,500 D without chemical crosslinking. PEG prepolymers 
can be readily formed by acrylation of the hydroxyl groups 
at its termini or elsewhere within the chain. These prepoly 
mers can be readily polymerized. Photoinitiated polymer 
ization of these prepolymerS is particularly convenient and 
rapid. There are a variety of visible light initiated and 
ultraViolet light initiated reactions that are initiated by light 
absorption by Specific photochemically reactive dyes. This 
Same approach can be used with other water-Soluble 
polymers, Such as poly(N-vinyl pyrrolidinone), poly(N- 
isopropyl acrylamide), poly(ethyl oxazoline) and many oth 
CS. 
Method for Formation of Polymeric Materials. 
Polymeric objects are formed into a desired shape by 
Standard techniques known to those skilled in the art, where 
the macromer Solution, preferably containing catalyst and 
initiator, is shaped, then polymerized. For example, Slabs 
may be formed by casting on a flat Surface and discoidal 
shapes by casting into discoidal containers. Cylinders and 
tubes can be formed by extrusion. Spheres can be formed 
from emulsion oil, by co-extrusion with oil, or by 
co-extrusion with air, another gas or vapor. The macromer is 
then exposed to conditions Such as light irradiation, to 
initiate polymerization. Such irradiation may occur Subse 
quent to, or, when desired, Simultaneously with the shaping 
procedures. 
The macromer may also be shaped in relationship to an 
internal or external Supporting Structure. Internal Supporting 
Structures include Screening networks of Stable or degrad 
able polymers or nontoxic metals. External Structures 
include, for example, casting the gel within a cylinder So that 
the internal Surface of the cylinder is lined with the gel 
containing the biological materials. 
Method for Surface Coating. 
These materials can be applied to the treatment of mac 
rocapsular Surfaces, Such as those used for ultrafiltration, 
hemodialysis and non-microencapsulated immunoisolation 
of animal tissue. The microcapsule in this case will usually 
be microporous with a molecular weight cutoff below 












module, a flat sheet or other configuration. The Surface of 
Such a microcapsule can be modified using a polymer Such 
as PEG to produce a non-fouling, non-thrombogenic, and 
non-cell-adhesive Surface. The coating Serves to enhance 
biocompatibility and to offer additional immunoprotection. 
Materials which can be modified in this manner include 
polysulfones, cellulosic membranes, polycarbonates, 
polyamides, polyimides, polybenzimidazoles, nylons, poly 
(acrylonitrile-co-Vinyl chloride) copolymers, polyurethanes, 
polystyrene, poly(styrene co-acrylonitriles), poly(Vinyl 
chloride), and poly(ethylene terephthalate). 
A variety of methods can be employed to form biocom 
patible overcoats, depending on the physical and chemical 
nature of the Surface. Hydrophilic Surfaces can be coated by 
applying a thin layer (for example, between 50 and 300 
microns in thickness) of a polymerizable Solution Such as 
PEG diacrylate containing appropriate amounts of dye and 
amine. Hydrophobic surfaces can be first rendered hydro 
philic by gas plasma discharge treatment and the resulting 
Surface can then be similarly coated, or they may simply be 
treated with a surfactant before or during treatment with the 
PEG diacrylate solution. For example, a hydrophobic poly 
styrene Surface could first be treated by exposure to an O. 
plasma or an N plasma. This results in rendering the Surface 
more hydrophilic by the creation of oxygen-containing or 
nitrogen containing Surface Species, respectively. These spe 
cies could be further treated by reaction with a substance 
Such as acryloyl chloride, capable of producing Surface 
bound free radical Sensitive Species. Alteratively, a hydro 
phobic polystyrene Surface could first be treated with a 
Surfactant, Such as a poly(ethylene oxide)-poly(propylene 
oxide) block copolymer, which could Subsequently be acry 
lated if desired. Such treatments would result in enhanced 
adhesion between the hydrophilic coating layerS and the 
hydrophobic material being treated. 
Treatment of Textured Materials and Hydrogels. 
The Surface of materials having a certain degree of 
Surface texture, Such as woven dacron, dacron Velour, and 
expanded poly(tetrafluoro-ethylene) (ePTFE) membranes, 
can be treated with the hydrogel. Textured and macroporous 
surfaces allow greater adhesion of the PEG gel to the 
material Surface, allowing the coating of relatively hydro 
phobic materials such as PTFE and poly(ethylene 
terephalate) (PET). 
Implantable materials. Such as enzymatic and ion Sensitive 
electrodes, having a hydrogel (Such as poly(HEMA), 
crosslinked poly(Vinyl alcohol) and poly(Vinyl 
pyrrolidone)), on their Surface, are coated with the more 
biocompatible PEO gel in a manner similar to the dye 
adsorption and polymerization technique used for the 
alginate-PLL microSpheres in the following examples. 
Treatment of Dense Materials. 
Gen coatings can be applied to the Surfaces of dense (e.g., 
nontextured, nongel) materials such as polymers, including 
PET, PTFE, polycarbonates, polyamides, polysulfones, 
polyurethanes, polyethylene, polypropylene, polystyrene, 
glass, and ceramics. Hydrophobic Surfaces are initially 
treated by a gas plasma discharge or Surfactant to render the 
Surface hydrophilic. This ensures better adhesion of the gel 
coating to the Surface. Alternatively, coupling agents may be 
used to increase adhesion, as readily apparent to those 
skilled in the art of polymer Synthesis and Surface modifi 
cation. 
Thin Interfacially Polymerized Coatings Within Blood Ves 
sels and Upon Other Tissues. 
The methodology described above can also be used to 
photopolymerize very thin films of non-degradable polymer 
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coatings with blood vessels to alter the interaction of blood 
platelets with the vessel wall and to deliver therapeutics such 
as enzymes and other proteins, polysaccharides Such as 
hyaluronic acid, nucleic acids Such as antisense and 
ribozymes, and other organic and inorganic drugs, using the 
methods described above. 
The immediate effect of the polymerization of the poly 
mer inside blood vessels is to reduce the thrombogenicity of 
an injured blood vessel Surface. This has clear utility in 
improving the outcome of balloon angioplasty by reducing 
the thrombogenicity of the vessel and reducing the incidence 
of lesions created by balloon dilatation. Another effect of 
this modification may be to reduce Smooth muscle cell 
hyperplasia. This is expected for two reasons. First, platelets 
contain a potent growth factor, platelet-derived growth fac 
tor (PDGF), thought to be involved in post-angioplasty 
hyperplasia. The interruption of the delivery of PDGF itself 
poses a pharmacological intervention, in that a "drug' that 
would have been delivered by the platelets would be pre 
vented from being delivered. Thrombosis results in the 
generation of thrombin, which is a known Smooth muscle 
cell mitogen. The interruption of thrombin generation and 
delivery to the vessel wall also poses a pharmacological 
intervention. Moreover, there are other growth factors 
Soluble in plasma which are known to be Smooth muscle cell 
mitogens. The gel layer presents a permselective barrier on 
the Surface of the tissue, and thus the gel layer is expected 
to reduce hyperplasia after angioplasty. Further, the gel may 
reduce vasospasm by protecting the vessel from exposure to 
vasoconstrictorS Such as thrombin and may reduce the 
incidence of acute reclosure. 
The restriction of the polymerization at an interface is a 
very important advantage. Disease lesions inside a blood 
vessel are highly irregular in shape. Thus, it is very difficult 
to use a preshaped object, Such as a balloon, to make a form 
which is to contain the polymerizing material adjacent to the 
blood vessel. 
There are Several other organs where one needs to control 
cell interaction with tissueS or to create Similar barriers by 
bulk or interfacial polymerization. This methodology is 
equally applicable to the other organs, as well as to encap 
Sulation of Specific cell types or biologically active materials 
Such as enzymes for treatment of various metabolic defects 
and diseases, for example, as described below. 
(i) Encapsulation of Neurotransmitter-Releasing cells. 
Paralysis agitans, more commonly called Parkinson's 
disease, is characterized by a lack of the neurotransmitter 
dopamine within the striatum of the brain. Dopamine Secret 
ing cells Such as cells from the Ventral mesencephalon, from 
neuroblastoid cell lines or from the adrenal medulla can be 
encapsulated using the method and materials described 
herein. Cells, including genetically engineered cells, Secret 
ing a precursor for a neurotransmitter, an agonist, a deriva 
tive or a mimic of a particular neurotransmitter or analogs 
can also be encapsulated. 
(ii) Encapsulation of Hemoglobin for Synthetic Erythrocytes 
Hemoglobin in its free form can be encapsulated in PEG 
gels and retained by Selection of a PEG chain length and 
cross-link density which prevents diffusion. The diffusion of 
hemoglobin from the gels may be further impeded by the use 
of polyhemoglobin, which is a croSS-linked form of hemo 
globin. The polyhemoglobin molecule is too large to diffuse 
from the PEG gel. Suitable encapsulation of either native or 
crosslinked hemoglobin may be used to manufacture Syn 
thetic erythrocytes. The entrapment of hemoglobin in Small 
Spheres of less than 5 microns in diameter of these highly 











times relative to crosslinked hemoglobin or liposome encap 
Sulated hemoglobin. 
(iii) Entrapment of Enzymes for correction of Metabolic 
Disorders and Chemotherapy. 
There are many diseases and defects which result from a 
deficiency in enzymes. For example, congenital deficiency 
of the enzyme catalase causes acatalasemia. Immobilization 
of catalase in PEG gel networks could provide a method of 
enzyme replacement to treat this disease. Entrapment of 
glucosidase can Similarly be useful in treating Gaucher's 
disease. MicroSpherical PEG gels entrapping urease can be 
used in extracorporeal blood to convert urea into ammonia. 
Enzymes Such as asparaginase can degrade amino acids 
needed by tumor cells. Immunogenicity of these enzymes 
prevents direct use for chemotherapy. Entrapment of Such 
enzymes in immunoprotective PEG gels, however, can Sup 
port Successful chemotherapy. A Suitable formulation can be 
designed for either slow release or no release of the enzyme. 
(iv) Cellular Microencapsulation for Evaluation of Anti 
Human Immunodeficiency Virus Drugs. In Vivo 
HIV infected or uninfected human T-lymphoblastoid cells 
can be encapsulated into PEG gels as described for other 
cells above. These microcapsules can be implanted in a 
nonhuman animal and then treated with test drugs. After 
treatment, the microcapsules can be harvested and the 
encapsulated cells Screened for viability and functional 
normalcy. Survival of infected T cells indicates successful 
action of the drug. Lack of biocompatibility is a documented 
problem in this approach to drug evaluations, but the highly 
biocompatible gels described herein should solve this prob 
lem. 
(v) Polymerization of Structural Coatings within Blood 
Vessels and Other Tissue Lumens. 
Just as very thin intravascular coatings can be polymer 
ized within blood vessels, thicker layers of Structural gels 
may also be polymerized within vessels. These may be used 
to reduce abrupt reclosure, to hold back vessel wall 
disections, to resist vasospasm, or to reduce Smooth muscle 
cell hyperplasia. These gels may be produced by bulk or 
interfacial polymerization, and the thicker and higher the 
crosslink density of the material, the Stronger the Structure 
within the vessel wall. This procedure could be carried out 
upon or within many organs of the body. 
The following examples are presented to describe pre 
ferred embodiments and utilities of the present invention and 
are not meant to limit the invention unless otherwise Stated 
in the claims appended hereto. Taken together, the examples 
illustrate representative demonstrations of the best mode of 
implementing the invention as currently understood. 
EXAMPLE 1. 
Synthesis of PEG 6 K Diacrylate. 
PEG acrylates of molecular weights 400 Da and 1,000 Da 
are commercially available from Sartomer and Dajac Inc., 
respectively. 20 g of PEG 6K diol was dissolved in 200 ml 
dichloromethane in a 250 ml round bottom flask. The flask 
was cooled to 0°C. and 1.44 ml of triethyl amine and 1.3 ml 
of acryloyl chloride were added with constant Stirring under 
a dry nitrogen atmosphere. The reaction mixture was then 
brought to room temperature and was stirred for 12 hr under 
a nitrogen atmosphere. It was then filtered, and the filtrate 
was precipitated by adding to a large excess of hexane. The 
crude monomer was purified by dissolving in dichlo 
romethane and precipitating in hexane. Yield 60%. 
EXAMPLE 2 
Synthesis of PEG 18.5 K Tetraacrylate. 
30g of a tetrahydroxy water soluble PEG (molwt 18,500) 
(PEG 18.5 k) was purchased from Polysciences, Inc. 
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The PEG was dried by dissolving in benzene and distill 
ing off the water-benzene azeotrope. 59 g of PEG 18.5k was 
dissolved in 300 ml of benzene in a 500 ml flask. To this, 3.6 
ml of triethylamine and 2.2 ml of acryloyl chloride were 
added under nitrogen atmosphere and the reaction mixture 
was refluxed for 2 hours. It was then cooled and stirred 
overnight. The triethyl amine hydrochloride was separated 
by filtration and the copolymer was recovered from filtrate 
by precipitating in a large excess of hexane. The polymer 
was further purified by dissolving in methylene chloride and 
reprecipitating in hexane. The polymer was dried at 50 C. 
under vacuum for 1 day. Yield 68%. 
EXAMPLE 3 
Coating of Islet-Containing Alginate-PLL Microspheres by 
Surface Dye Adsorption. 
The microcapsule interfacial polymerization method was 
used to form membrane around alginate-PLL microcapsules 
containing islets. Alginate-PLL coacervated microSpheres, 
containing one or two human pancreatic islets each, were 
Suspended in a 1.1% CaCl Solution and aspirated free of 
exceSS Solution to obtain a dense plug of microSpheres. A 
solution of ethyl eosin (0.04% w/v) was prepared in a 1.1% 
CaCl Solution. This Solution was filter-Sterilized by passage 
through a 0.45 um filter. The plug of microSpheres was 
suspended in 10 ml of the eosin solution for 2 minto allow 
uptake of the dye. The microSpheres were then washed four 
times with fresh 1.1% CaCl to remove excess dye. 2 ml of 
a solution (23% w/v) of PEG 18.5 tetraacrylate containing 
100 ul of a 3.5% w/v solution of triethanolamine in hydroxy 
ethylpiperazine ethanesulfonic acid (HEPES) buffered 
saline was added to 0.5 ml of these microspheres. The 
microbpheres were exposed to argon ion laser light for 30 
Seconds with periodic agitation. The Suspension of micro 
Spheres was uniformly Scanned with the light during this 
period. The microSpheres were then washed with calcium 
Solution and the process was repeated in order to further 
Stabilize the coating. 
A static glucose stimulation test (SGS) was performed on 
islets-encapsulated in the microspheres coated with PEG 
gel. Data for insulin Secretion in response to this challenge 
appears in Table 1. The islets are seen to be viable by 
dithizone staining. The SGS test data confirm the vitality and 
functionality of the islets. 
TABLE 1. 
Function of Encapsulated Islet Cells SGS 
Glucose Concentration (mg % 
Initial Subsequent 
60 3OO 60 
Insulin/Islet/hr (u J/ml)* 
Diffusion Overcoat Method 1.O 10.043.56 2.54 - 0.76 
Mineral Oil Overcoat Method 1.O 10.23 - 3.28 1.O2 - 0.78 
Free Islet Control 1.O 3.74 - 1.4 1.9 0.17 
* Values are mean + S.D., all are normalized as compared to the initial 60 
mg%, after subjection to the 300 mg% glucose, the islets are resubjected 
to the initial dose. 
PEG diacrylate macromers can be polymerized identi 
cally as the PEG tetraacrylate macromer described in this 
example. 
EXAMPLE 4 
Coating Islet-Containing Alginate-PLL MicroSpheres Sus 
pension Polymerization Method 
This method takes advantage of the hydrophilic nature of 











taining one or two human pancreatic islets each, were mixed 
with PEG tetraacrylate macromer solution (PEG mol wt 
18.5 kD, 23% solution in saline) in a 50 ml transparent 
centrifuge tube. Triethanolamine (0.1 M) and 0.5 mMethyl 
eosin were mixed with macromer Solution. The exceSS 
macromer Solution was decanted, 20 ml of mineral oil was 
added to the tube, and the reaction mixture was Vortexed 
thoroughly for 5 minutes. Silicone oil will perform equally 
well in this Synthesis but may have poorer adjuvant char 
acteristics if there is any carry-over. Any other water 
immiscible liquid may be used as the “oil” phase. Accept 
able triethanolamine concentrations range from about 1 mM 
to about 100 mM. Acceptable ethyl eosin concentrations 
range from about 0.01 mM to more than 10 mM. 
The beads were slightly red due to the thin coating of 
macromer/dye solution and were irradiated for 20-50 sec 
with an argon ion laser (power 50-500 mW). Bleaching of 
the (red) ethyl eosin color Suggests completion of the 
reaction. The beads were then Separated from the mineral oil 
and washed several times with Saline Solution. The entire 
procedure was carried out under Sterile conditions. 
A Schematic representation of the macroSphere coating 
process in oil is shown in FIG. 3. Alginate/polylysine 
capsules are soluble in Sodium citrate at pH 12. When these 
coated microSpheres come in contact with Sodium citrate at 
pH 12, the inner alainate/polylysine coacervate dissolves 
and a PEG polymeric membrane can still be seen 
(crosslinked PEG gels are substantially insoluble in all 
Solvents including water and Sodium citrate at pH 12). The 
uncoated control microSpheres dissolve completely and rap 
idly in the same Solution. 
A Static glucose challenge was performed on the islets as 
in Example 3. Data are also shown in Table 1. The islets are 
viable and functional. 
EXAMPLE 5 
Encapsulation of Islets of Langerhans 
This example makes use of the direct interfacial polymer 
ization. Islets of Langerhans isolated from a human pancreas 
were encapsulated in PEG tetraacrylate macromer gels. 500 
islets suspended in RPMI 1640 medium containing 10% 
fetal bovine serum were pelleted by centrifuging at 100 g for 
3 min. The pellet was resuspended in 1 ml of a 23% w/v 
solution of PEG 18.5 K tetraacrylate macromer in HEPES 
buffered saline. 5 ul of an ethyl eosin solution in vinyl 
pyrrolidone (at a concentration of 0.5%) was added to this 
solution along with 100 ul of a 5M solution of triethano 
lamine in Saline. 20 ml of a mineral oil was then added to the 
tube which was vigorously agitated to form a dispersion of 
droplets 200-500 um in size. This dispersion was then 
exposed to an argon ion laser with a power of 250 mW, 
emitting at 514 nm, for 30 sec. The mineral oil was then 
Separated by allowing the microSpheres to Settle, and the 
resulting microSpheres were washed twice with phosphate 
buffered saline (PBS), once with hexane and three times 
with media. 
The Vialility of Islets of Langerhans encapsulated in a 
PEG-tetraacrylate gel was verified by an acridine orange and 
propidium iodide Staining method and also by dithizone 
Staining. In order to test functional normalcy, a SGS test was 
performed on these islets. The response of the encapsulated 
islets was compared to that of free islets maintained in 
culture for the Same time period. All islets were maintained 
in culture for a week before the SGS was performed. The 
results are Summarized in Table 2. It can be seen that the 
encapsulated islets Secreted significantly (p<0.05) higher 
amounts of insulin than the free islets. The PEG 
tetraacrylate gel encapsulation process did not impair func 
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tion of the islets and in fact helped them maintain their 
function in culture better than if they had not been encap 
Sulated. 
TABLE 2 
Secretion of Insulin from Islet Cells 
Islet Insulin Secretion 
Glucose Concentration (mg % 
60 3OO 60 
Insulin/islet/hr (ul J/ml)* 
Free islets 1.O 3.74 - 140 1.9 O.17 
Encapsulated Islets 1.O 20.81 - 9.36 2.0 - 0.76 
* Values are mean + S.D., normalized to initial basal level at 60 mg% 
glucose. 
EXAMPLE 6 
Microencapsulation of Animal Cells. 
PEG diacrylates of different molecular weight were syn 
thesized by a reaction of acryloyl chloride with PEG as in 
Example 1. A 20 to 30% solution of macromer was mixed 
with a cell Suspension and the ethyl eosin and triethanola 
mine initiating System before exposing it to laser light 
through a coextrusion air flow apparatus shown in FIG. 4. 
MicroSpheres were prepared by an air atomization process in 
which a stream of macromer was atomized by an annular 
stream of air. The air flow rate used was 1,600 cc/min and 
macromer flow rate was 0.5 ml/min. The droplets were 
allowed to fall into a petri dish containing mineral oil and 
were exposed to laser light for about 0.15 Sec each to 
polymerize the microSpheres and make them insoluble in 
water. The microspheres were separated from the oil and 
thoroughly washed with PBS buffer to remove unreacted 
macromer and residual initiator. The Size and shape of the 
microspheres was dependent on extrusion rate (0.05 to 0.1 
ml/min) and extruding capillary diameter (18 Ga to 25 Ga). 
The polymerization times were dependent on initiator con 
centration (ethyl eosin concentration (5 uM to 0.5 mM), 
vinyl pyrrolidone concentration (0.0% to 0.1%), triethano 
lamine concentration (5 to 100 mM), laser power (10 mW to 
1W), and macromer concentration (greater than 10% w/v). 
A PEG diacrylate macromer of molecular weight 400 Da 
was used as a 30% solution in PBS, containing 0.1 M 
triethanolamine as a cocatalyst and 0.5 mM ethyl eosin as a 
photoinitiator. The polymerizations were carried out at 
physiological pH in the presence of air. This is significant 
Since radical polymerizations may be affected by the pres 
ence of oxygen, and the acrylate polymerization is still rapid 
enough to proceed effectively. 
The proceSS also works at lower temperatures. For cellular 
encapsulation, a 23% solution of PEG diacrylate was used 
with initiating and polymerization conditions as used in the 
air atomization technique. Cell viability Subsequent to 
encapsulation was checked with the trypan blue exclusion 
assay. Human foreskin fibroblasts (HFF), Chinese hamster 
ovary cells (CHO-Kl), and a beta cell insuloma line (RiN5F) 
were found to be viable (more than 95%) after encapsula 
tion. A wide range of PEG diacrylate concentrations greater 
than 10% can be used equally effectively, as can PEG 
tetraacrylate macromers. 
EXAMPLE 7 
coating of Animal Cell-Containing Alginate-PLL Micro 
spheres and Individual Cells by Surface Dye Adsorption. 
Alginate-PLL coacervated microSpheres containing ani 











aspirated free of exceSS Solution to obtain a dense plug of 
microSpheres. The plug of microSpheres was Suspended in 
10 ml of eosin solution for 2 minto allow dye uptake. 2 ml 
of a solution (23% w/v) of PEG 18.5 tetraacrylate containing 
100 All of a 3.5 w/v Solution of triethanolamine in HEPES 
buffered saline was added to 0.5 ml of these microspheres. 
The microSpheres were exposed to an argon ion laser for 30 
Seconds with periodic agitation. The Suspension of micro 
Spheres was uniformly Scanned with the laser during this 
period. The microSpheres were then washed with calcium 
Solution and the proceSS was repeated once more in order to 
attain a stable coating. 
In order to verify survival of cells after the overcoat 
process, cells in Suspension without the alginate/PLL micro 
capsule were exposed to Similar polymerization conditions. 
1 ml of lymphoblastic leukemia cells (RAJI) (5x10 cells) 
was centrifuged at 300 g for 3 min. 1 ml of a 0.04% filter 
Sterilized ethyl eosin Solution was phosphate buffered Saline 
(PBS) is added and the pellet was resuspended. The cells 
were exposed to the dye for 1 min and washed twice with 
PBS and then pelleted. 10 ul of triethanolamine solution (0.1 
M) was added to the pellet and the tube was vortexed to 
resuspend the cells. 0.5 ml of PEG 18.5 K tetraacrylate 
macromer was then mixed into this Suspension and the 
resulting mixture exposed to an argon ion laser (514 nm, 50 
mW) for 45 sec. The cells were then washed twice with 10 
ml saline and once with media (RPMI 1640 with 10% FCS 
and 1% antibiotic, antimycotic). A thin membrane of PEG 
tetraacrylate gel was observed forming around each indi 
vidual cell. 
No significant difference in viability was seen between the 
control population (93% viable) and the treated cells (95% 
viable) by trypan blue exclusion. An assay for cell viability 
and function was performed by adapting the MTT-Formazan 
assay for the RAJI cells. This assay indicates greater than 
90% survival. Similar assays were performed with two other 
model cell lines. Chinese hamster ovary cells (CHO-Kl) 
show no significant difference (p<0.05) in metabolic func 
tion as evaluated by the MTT-Formazan assay. 3T3 mouse 
fibroblasts also show no significant reduction (p20.50) in 
metabolic activity. 
EXAMPLE 8 
Coating Animal Cell Containing Alginate-PLL Microsphere 
Suspension Polymerization Method. 
Using the method described in Example 4, RAJI cells 
encapsulated in alginate-PLL microSpheres were coated 
with a PEG 18.5 K tetraacrylate polymeric membrane. 
Viability of these cells was checked by trypan blue exclusion 
and found to be more than 95% viable. 
EXAMPLE 9 
Coating of Individual Islets of Langerhans by Surface Dye 
Adsorption. 
Using the method described in Example 7, ethyl eosin was 
adsorbed to the Surfaces of islets, a Solution of the PEG 
macromer with triethanolamine was applied to the dye 
coated cells, and the cells were exposed to light from an 
argon-ion laser to form a thick PEG polymeric membrane on 
the surface of the islets. Islet viability was demonstrated by 
lack of Staining with propidium iodide. 
EXAMPLE 10 
Biocompatibility of PEG on Microspheres. 
In Vivo evaluation of the extent of inflammatory response 
to microSpheres prepared in Examples 7 and 8 was carried 
out by implantation in the peritoneal cavity of mice. 
Approximately 0.5 ml of microSpheres were Suspended in 5 
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ml of sterile HEPES buffered saline. 2.5 ml of this suspen 
Sion was injected into the peritoneal cavity of ICR male 
Swiss white mice. The microSpheres were recovered after 4 
days by lavage of the peritoneal cavity with 5 ml of 10U 
heparin/ml PBS. The extent of cellular growth on the 
microSpheres was visually inspected under a phase contrast 
microScope. The number of unattached cells present in the 
recovered lavage fluid was counted using a Coulter counter. 
Photographs were taken of alginate-poly(L-lysine) micro 
Spheres recovered after 4 days, and Similar spheres which 
had been coated with PEG gel by the dye diffusion process 
before implantation. AS expected, bilayer alginate 
polylysine capsules not containing an outer alginate layer 
were completely covered with cells due to the highly cell 
adhesive nature of the PLL Surface, whereas the PEG coated 
microSpheres were Virtually free of adherent cells. Almost 
complete coverage of alginate-poly(L-lysine) was expected 
because polylysine has amino groups on the Surface, and 
positively charged Surface amines can interact with cell 
Surface proteoglycans and Support cell growth (Reuveny, et 
al., (1983) Biotechnol. Bioeng, 25:469-480). The photo 
graphs strongly indicate that the highly charged and cell 
adhesive surface of PLL is covered by a stable layer of PEG 
gel. The integrity of the gel did not appear to be compro 
mised. 
The non-cell-adhesive-tendency of these microSpheres 
was evaluated as a percentage of the total microSphere area 
which appears covered with cellular Overgrowth. These 
results are Summarized in Table 3. 
TABLE 3 
Microsphere Coverage with Cell Overgrowth Following 
Implantation Intraperitoneally for 4 Days. 
Composition of PEG gel % Cell coverage 
18.5 K. <1 
18.5k 90%:0.4 k 10% <1 
18.5 k50%:0.4 k 50% <1 
35 k 90%:0.4 k 10% 5-7 
35 k 50%:0.4 k50% <1 
Alginate-poly(L-lysine) 60-80 
An increase in cell count is a result of activation of 
resident macrophages which Secrete chemical factorS Such 
as interleukins and induce nonresident macrophages to 
migrate to the implant Site. The factorS also attract fibro 
blasts responsible. for collagen Synthesis. The variation of 
cell counts with chemical composition of the overcoat is 
shown FIG. 5. It can be seen from the figure that all PEG 
coated Spheres have Substantially reduced cell counts. This 
is consistent with the PEG overcoat generally causing no 
irritation of the peritoneal cavity. 
However, PEG composition does make a difference in 
biocompatibility, and increasing molecular weights are asso 
ciated with a reduction in cell counts. This could be due to 
the gels made from higher molecular weight oligomers 
having higher potential for Steric repulsion due to the longer 
chain lengths. 
EXAMPLE 11 
Permeability of PEG Gels. 
20 mg of bovine Serum albumin, human IgG, or human 
fibrinogen was dissolved in 2 ml of a 23% w/v solution of 
oligomeric PEG 18.5 k tetraacrylate in PBS. This solution 
was laser polymerized to produce a gel 2 cmx2 cmx0.5 cm 
in size. The diffusion of bovine serum albumin, human IgG 
and human fibrinogen (mol wt 66 kDa, 150 kDa and 350 











face of these gels using a total protein assay reagent 
(Biorad). A typical release profile for a PEG 18.5 K gel was 
shown in FIG. 6. This gel allowed a slow transport of 
albumin but did not allow IgG and fibrinogen to diffuse. This 
indicates that these gels are capable of being used as 
immunoprotective barriers. This is a vital requirement for a 
Successful animal tissue microencapsulation material. 
The release profile was found to be a function of crosslink 
density and molecular weight of the polyethylene glycol 
segment of the monomer. FIG. 7 shows the release of bovine 
serum albumin (BSA) through gels made from 23% solu 
tions of PEO diacrylates and tetraacrylates of 0.4K and 18.5 
K, respectively. It is evident that the 18.5 K gel was freely 
permeable to albumin while the 0.4 K gel restricted the 
diffusion of albumin. The release of any substance from 
these gels depends on the crosslink density of the network 
and also depends on the motility of the PEG segments in the 
network. This effect was also dependent upon the function 
ality of the macromer. For example, the permeability of a 
PEG 18.5 K tetraacrylate gel was less than that of an 
otherwise similar PEG 20 K diacrylate gel. 
EXAMPLE 12 
Treatment of Silicone Rubber to form PEG Gel Layer to 
Enhance Biocompatibility. 
2x2 cm pieces of medical grade Silicone rubber were 
soaked for 1 h in benzene containing 23% 0.4 k PEG 
diacrylate and 0.5%. 2,2-dimethoxy-2-phenyl acetophenone. 
The Swollen rubber was irradiated for 15 min with a long 
wave UV lamp (365 nm). After irradiation, the sample was 
rinsed in benzene and dried. The air contact angles of 
silicone rubber under water were measured before and after 
treatment. The decreased contact angle of 500 after 
treatment, over the initial contact angle of 630 for untreated 
Silicone rubber, reflects an increased hydrophilicity due to 
the presence of the PEG gel on the rubber surface. 
This technique demonstrates that macromer polymeriza 
tion can be used to modify a polymer Surface So as to 
enhance biocompatibility. For instance, a polyurethane cath 
eter can be treated by this method to obtain an implantable 
device coated with PEG. The PEG was firmly anchored 
anchored to the Surface of the polyurethane catheter because 
the macromer was allowed to penetrate the catheter Surface 
(to a depth of 1–2 microns) during the Soaking period before 
photopolymerization. Upon irradiation, an interpenetrating 
network of PEG and polyurethane results. The PEG was 
thereby inextricably intertwined with the polyurethane. 
EXAMPLE 13 
Rate of Polymerization. 
The kinetics of a typical reaction were determined to 
demonstrate rapidity of gelation in laser-initiated polymer 
izations of multifunctional acrylic monomers. 
Trimethylolpropyl-triacrylate, containing 5x10" M ethyl 
eosin as a photoinitiator in 10 tumoles of N-vinyl pyrrolidone 
per ml of macromer mix and 0.1 M of triethanolamine as a 
cocatalyst, was irradiated with a 500 mW argon ion laser 
(514 nm wavelength, power 3.05x10 W/m, beam diameter 
1 mm, average gel diameter produced 1 mm). A plot of the 
length of the Spike of gel formed by penetration of the laser 
beam into the gel verSuS laser irradiation time is showen in 
FIG. 8. 
100 ul of a 23% w/w solution of various macromers in 
HEPES buffered saline containing 3 ul of initiator Solution 
(300 mg/ml of 2.2 dimethoxy-2-phenoxyacetophenone in 
N-Vinyl pyrrolidone) was placed on a glass coverslip and 
irradiated with a low intensity long wave UV (LWUV) lamp 
(Black-Ray, model 3-100A with flood). The times required 
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for gelation to occur were noted and are given in Table 4. 
These times are typically in the range of 10 Seconds. 
TABLE 4 
Gelling Times of Irradiated Polymer 
Gel Time (sec) 
Polymer Size (mean + S.D.) 
O.4 K 6.9 0.5 
1 K 21.3 2.4 
6 K 14.2 + 0.5 
1OK 8.3 O2 
18.5 K. 6.9 O.1 
2OK 9.0 O.4 
Time periods of about 10-100 ms are sufficient to gel a 
300 um diameter droplet, a typical Size of gel used in 
microencapsulation technology. This rapid gelation, if used 
in conjunction with proper choice of macromers, can lead to 
entrapment of living cells in a three dimensional covalently 
bonded polymeric network. Monochromatic laser light will 
not be absorbed by the cells unless a proper chromophore is 
present, and is considered to be harmless if the wavelength 
is more than about 400 nm. Exposure to long wavelength 
ultraViolet light, greater than 360 nm, is harmless at practical 
intensities and durations. 
The polymerization rate of the macromer will depend on 
the macromer concentration, the initiator concentration, and 
the functionality of the macromer, e.g., the difunctionality of 
a PEG diacrylate or the tetrafunctionality of a PEG 
tetraacrylate, as well as the degree of acrylation of the 
material. 
EXAMPLE 1.4 
PEG Gel Interactions. 
Biocompatibility with HFF (human foreskin fibroblasts) 
cells was demonstrated as follows. HFF cells were seeded on 
PEG 18.5 K tetraacrylate gels at a density of 18,000 cells/ 
cm in Dulbecco's modification of Eagle's medium contain 
ing 10% fetal calf serum. The gels were then incubated at 
37° C. in a 5% CO environment for 4 hr. At the end of this 
time the gels were washed with PBS to remove any non 
adherent cells and were observed under a phase contrast 
microScope at a magnification of 200X. 
The growth of these cells on a typical PEG gel was as 
compared to the growth of these cells on a glass Surface. The 
number of attached cells/cm was found to be 510+170 on 
the gel surfaces as compared to 13,200+3,910 for a control 
glass Surface. The cells on these gels appeared rounded and 
were not in their normal spread morphology, Strongly indi 
cating that these gels do not encourage cell attachment. 
Biocompatibility on microSpheres was demonstrated as 
follows. A photograph of microSpheres explanted from mice 
as in Example 10 was taken; after 4 days very little fibrous 
overgrowth is seen. The resistance of PEG chains to protein 
adsorption and hence cellular growth is well documented. 
Table 5 summarizes the extent of cellular overgrowth seen 
on these microspheres formed of various PEG diacrylate 
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Characterization and Mechanical Analysis of PEG Gels. 
10 ul of an initiator Solution containing 30 mg/ml of 
2,2-dimethoxy-2-phenyl acetophenone in Vinyl-2- 
pyrrolidone was added per ml to 23% w/v solutions of PEG 
diacrylates (0.4K, 6 K, 10 K) and PEG tetraacrylates (18.5 
K). The Solution of initiator containing macromer was 
placed in a 4.0x1.0x0.5 cm mold and exposed to a long wave 
ultraviolet lamp (365 nm) for approximately 10 seconds to 
induce gelation. Samples were allowed to equilibrate in 
phosphate buffered saline (pH 7.4) for 1 week before analy 
sis was performed. 
A series of “dogbone' Samples (samples cut from a slab 
into the shape of a dogbone, with wide regions at both ends 
and a narrower long region in the middle) were cut from 
ultimate tensile Strength tests. Thickness of the Samples was 
defined by the thickness of the sample from which they are 
cut. These thicknesses ranged from approximately 0.5 mm 
to 1.75 mm. The samples were 20 mm long and 2 mm wide 
at a narrow “neck” region. The stress strain tests were run in 
length control at a rate of 4% per Second. After each test, the 
croSS Sectional area was determined. Table 6 shows the 
ultimate tensile Strength data. It is seen that the lower 
molecular weight macromers in general give Stronger gels 
which are leSS eXtensible than those made using the higher 
molecular weight macromers. The PEG 18.5 K tetraacrylate 
gel is seen to be anomalous in this Series, resulting from the 
multifunctionality of the macromer and the corresponding 
higher crosslinking density in the resulting gel. This type of 
Strengthening result could be similarly obtained with mac 
romers obtained having other than four free radical-Sensitive 
groups, Such as acrylate groups. 
TABLE 6 
Gel Strength Tests 
PEG Acrylate Precursor Molecular Weight 
O4 K 6 K 1OK 18.5 K. 
Stress 168 +f-51 98 +f- 15 33 +f- 7 115 +/- 56 
(kpa)* 
% 8 +f-3 71 -f- 13 110 -f- 9 40 +f- 15 
Strain 
Slope 22 +f-5 1.32 +f- 0.31 O.27+f- 0.04 2.67 +f- 0.55 
Values are mean -f- S.D. 
For the creep tests, eight Samples approximately 0.2x 
0.4x2 cm were loaded while Submersed in Saline Solution. 
They were tested with a constant unique predetermined load 
for one hour and a Small recovery load for ten minutes. Gels 
made from PEG diacrylates of 1 K, 6K, and 10 K, and PEG 
tetraacrylates of 18.5 KPEG molecular weight were used for 
this study. The 10K test was terminated due to a limit error 
(the sample stretched beyond the travel of the loading 
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frame). The 1K sample was tested with a load of 10 g and 
a recovery load of 0.2g. The 6K Sample was tested at a load 
of 13 g with a recovery load of 0.5g. The 18.5 K sample was 
tested at a load of 13 g with a recovery load of 0.2 g. The 
choice of loads for these samples produced classical creep 
curves with primary and Secondary regions. The traces for 
creep for the 1 K, 6 K, and 18.5 K samples appear in FIGS. 
9A-C respectively. 
EXAMPLE 16 
Water Content of PEG Gels. 
Solutions of various macromers were made as described 
above. Gels in the shape of discS were made using a mold. 
400 ul of solution was used for each disc. The solutions were 
irradiated for 2 minutes to ensure thorough gelation. The 
disc shaped gels were removed and dried under vacuum at 
60° C. for 2 days. The discs were weighed (W1) and then 
extracted repeatedly with chloroform for 1 day. The discs 
were dried again and weighed (W2). The gel fraction was 
calculated as W2/W1. This data appears in Table 7. 
Subsequent to extraction, the discS were allowed to equili 
brate with HBS for 6 hours and weighed (W3) after excess 
water had been carefully Swabbed away. The total water 
content was calculated as (W3-W2)x100/W3. The data for 
gel water contents is Summarized in the following table. 
TABLE 7 
Data for gel water contents. 
Polymer Code % Total Water % Giel Content 
0.4 99.8 1.9 
1 K 79.8 2.1 94.5 + 2.0 
6 k 95.2 2.5 69.4 - 0.6 
10 k 914 - 1.6 96.9 - 1.5 
18.5 k 914 - 0.9 8O3 + O.9 
20 k 944 - 0.6 85.0 - 0.4 
EXAMPLE 1.7 
Mechanical Stability of PEG Gels after Implantation. 
PEG diacrylate (10 K) and PEG tetraacrylate (mol, wt. 
18.5 k) were cast in dogbone shapes as described in Example 
15. 23% w/w PEG-diacrylate or tetraacrylate in sterile 
HEPES buffered saline (HBS) (0.9% NaCl, 10 mM HEPES, 
pH 7.4), containing 900 ppm of 2,2-dimethoxy-2- 
phenoxyacetophenone as initiator, was poured into an alu 
minum mold and irradiated with a LWUV lamp (Black ray) 
for 1 min. The initial weights of these samples were found 
after oven-drying these gels to constant weight. The Samples 
were Soxhlet-extracted with methylene chloride for 36 hours 
in order to leach out any unreacted prepolymer from the gel 
matrix (sol-leaching), prior to testing. The process of extrac 
tion was continued until the dried gels gave constant weight. 
ICR Swiss male white mice, 6-8 weeks old (Sprague 
Dawley), were anesthetized by an intraperitoneal injection 
of sodium pentobarbital. The abdominal region of the mouse 
was shaved and prepared with betadine. A Ventral midline 
incision 10–15 mm long was made. The polymer Sample, 
fully hydrated in sterile PBS (Phosphate buffered saline) or 
HEPES buffered saline (for calcification studies), was 
inserted through the incision and placed over the mesentery, 
away from the wound site. The peritoneal wall was closed 
with a lock stitched running suture (4.0 silk, Ethicon). The 
skin was closed with Stainless Steel skin Staples, and a 
topical antibiotic (Furacin) was applied over the incision 
Site. Three animals were used for each time point. One 











the end of 1 week, 3 weeks, 6 weeks, and 8 weeks. Explanted 
gels were rinsed in HBS twice and then treated with 0.3 
mg/ml pronase (Calbiochem) to remove any adherent cells 
and tissue. The Samples were then oven-dried to a constant 
weight extracted and reSWelled as mentioned before. 
Tensile StreSS Strain test was conducted on both control 
(unimplanted) and explanted dogbones in a Small horizontal 
Instron-like device. The device is an aluminum platform 
consisting of two clamps mounted flat on a wooden board 
between two parallel aluminum guide. The top clamp is 
stationary while the bottom clamp is movable. Both the 
frictional Surfaces of the moving clamp and the platform are 
coated with aluminum backed Teflon (Cole-Parmer) to mini 
mize frictional resistance. The moving clamp is fastened to 
a device capable of applying a gradually increasing load. 
The whole Set-up is placed horizontally under a dissecting 
microscope (Reichert) and the Sample elongation is moni 
tored using a Video camera. The image from the camera is 
acquired by an image processor (Argus-10, Hamamatsu) and 
Sent to a monitor. After breakage, a croSS Section of the break 
Surface is cut and the area measured The load at break is 
divided by this cross section to find the maximum tensile 
stress. Table 8 lists the stress at fracture of PEG tetraacrylate 
(18.5 K) hydrogels explanted at various time intervals. No 
Significant change in tensile Strength is evident with time. 
Thus, the gels appear mechanically stable to biodegradation 
in Vivo within the maximum time frame of implant in mice. 
TABLE 9 
Resistance to degradation of Polymer Implants 
TIME STRESS (KPa) STRAINAVE. 
IMPLANTED (mean + error) (mean + error) 
1 WK 52.8 16.7 O.32 O.19 
3 WK 36.7 10.6 O.37 - 0.17 
6 WK 73.3 34.9 O.42 - 0.26 
8 WK 34.1#. O.30it 
CONTROL 44.95.3 O.22 - 0.22 
Error based on 90% confidence limits. 
#Single sample. 
EXAMPLE 1.8 
Monitoring of Calcification of PEG Gels. 
Disc shaped PEG-tetraacrylate hydrogels (mol. wt. 18.5 
k) were implanted intraperitoneally in mice as described 
above for a period of 1 week, 3 weeks, 6 weeks or 8 weeks. 
Explanted gels were rinsed in HBS twice and treated with 
Pronase (Calbiochem) to remove cells and cell debris. The 
samples were then equilibrated in HBS to let free Ca" 
diffuse out from the gel matrix. The gels were then oven 
dried (Blue-M) to a constant weight and transferred to 
Aluminum oxide crucibles (COORS, high temperature 
resistant). They were incinerated in a furnace at 700° C. for 
at least 16 hours. Crucibles were checked for total 
incineration, if any residual remnants or debris was seen 
they were additionally incinerated for 12 hours. 
Subsequently, the crucibles were filled with 2 ml of 0.5 M 
HCl to dissolve Ca' salt and other minerals in the sample. 
This Solution was filtered and analyzed with atomic absorp 
tion spectroscopy (AA) for calcium content. 
Calcification data on PEG-tetraacrylate (mol. wt. 18.5 K) 
gel implants is given in Table 9. No Significant increase in 
calcification was observed up to an 8 week period of 
implantation in mice. 
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TABLE 9 
Calcification data on PEG-tetraacrylate (mol. wt. 
18.5 K) gel implants 
TIME CALCIFICATION (mean + error) 
(Days) (mg Calcium/g of Dry gel wt.) 
7 2.33 - 0.2O 
21 O.88 O.OO9 
42 1.08 O.30 
56 1.17 O.26 
Error based on 90% confidence limits. 
EXAMPLE 1.9 
Use of PEG Gels as Adhesive to Rejoin Severed Nerve. 
A formulation of PEG tetraacrylate (10%, 18.5 K), was 
used as adhesive for Stabilizing the SutureleSS apposition of 
the ends of transected Sciatic nerves in the rat. Rats were 
under pentobarbital anesthesia during Sterile Surgical proce 
dures. The Sciatic nerve was exposed through a lateral 
approach by deflecting the heads of the biceps femoralis at 
the mid-thigh level. The sciatic nerve was mobilized for 
approximately 1 cm and transected with iridectomy Scissors 
approximately 3 mm proximal to the tibial-peroneal bifur 
cation. The gap between the ends of the Severed nerves was 
2-3 mm. The wound was irrigated with saline and lightly 
Swabbed to remove exceSS Saline. Sterile, unpolymerZed 
PEG tetraacrylate Solution was applied to the wound. Using 
delicate forceps to hold the adventitia or perineurium, the 
nerve ends were brought into apposition, the macromer 
Solution containing 2,2-dimethoxy-2- 
phenoxyacetophenone. as a photoinitiator applied to the 
nerve ends and the wound was exposed to long wavelength 
UV-light (365 nm) for about 10 sec to polymerize the 
adhesive. The forceps were gently pulled away. Care was 
taken to prevent the macromer Solution from flowing 
between the two nerve Stumps. Alternatively, the nerve 
Stump junction was Shielded from illumination, e.g., with a 
metal foil, to prevent gelation of the macroner Solution 
between the Stumps, the remaining macromer Solution was 
then simply washed away. 
In an alternative approach, both ends of the transected 
nerve can be held together with one pair of forceps. Forceps 
tips are coated lightly with petrolatum to prevent reaction 
with the adhesive. 
The polymerized adhesive Serves to encapsulate the 
wound and adhere the nerve to the underlying muscle. The 
anastomosis of the nerve ends resists gentle mobilization of 
the joint, demonstrating a moderate degree of Stabilization. 
The muscle and Skin were closed with Sutures. 
Re-examination after one month shows that Severed nerves 




Abdominal muscle flaps from female New Zealand white 
rabbits were excised and cut into strips 1 cmx5 cm. The flaps 
were approximately 0.5 to 0.8 cm thick. The lap joint, 1 
cmx1 cm, was made using two Such flaps. Two different 
PEO di- and tetra-acrylate macromer compositions, 0.4 K 
(di-) and 18.5 K (tetra-), were evaluated. The 0.4 K com 
position was a Viscous liquid and was used without further 
dilution. The 18.5 K composition was used as a 23% w/w 
solution in HBS. 125 ul of ethyl eosin solution in n-vinyl 
pyrrolidone (20 mg/ml) along with 50 ul of triethanolamine 











adhesive Solution was applied to each of the overlapping 
flaps. The lap joint was then irradiated by Scanning with a 2 
W argon ion laser for 30 seconds from each side. The 
Strength of the resulting joints was evaluated by measuring 
the force required to Shear the lap joint. One end of the lap 
joint was clamped and an increasing load was applied to the 
other end, while holding the joint horizontally until it failed. 
Four joints were tested for each composition. The 0.4 K 
joints had a strength of 12.0+6.9 KPa (meantS.D.), while 
the 18.5 K joints had a strength of 2.7+0.5 KPa. It is 
Significant to note that it was possible to achieve photopo 
lymerization and reasonable joint Strength despite the 6-8 
mm thickness of tissue. A Spectrophotometric estimate using 
514 nm light showed less than 1% transmission through 
Such muscle tissue. 
EXAMPLE 21 
Modification of Polyvinyl Alcohol. 
2 g of polyvinyl alcohol (mol wt 100,000-110,000) was 
dissolved in 20 ml of hot DMSO. The Solution was cooled 
to room temperature and 0.2 ml of triethylamine and 0.2 ml 
of acryloyl chloride was added with Vigorous stirring, under 
an argon atmosphere. The reaction mixture was heated to 
70° C. for 2 hr and cooled. The polymer was precipitated in 
acetone, redissolved in hot water and precipitated again in 
acetone. Finally it was dried under vacuum for 12 hr at 60 
C. 5-10% w/v solution of this polymer in PBS was mixed 
with the UV photoinitiator and polymerized using long 
wavelength UV light to make microspheres 200-1,000 
microns in size. 
These microSpheres were Stable to autoclaving in water, 
which indicates that the gel is covalently croSS-linked. The 
gel is extremely elastic. This macromer, PVA multiacrylate, 
may be used to increase the crosslinking density in PEG 
diacrylate gels, with corresponding changes in mechanical 
and permeability properties. This approach could be pursued 
with any number of water-soluble polymers chemically 
modified with photopolymerizable groups, for example with 
water-Soluble polymers chosen from polyvinylpyrrolidone, 
polyethyloxazoline, polyethyleneoxide-polypropyleneoxide 
copolymers, polysaccharides Such as dextran, alginate, 
hyaluronic acid, chondroitin Sulfate, heparin, heparin 
Sulfate, heparan Sulfate, guar gum, gellan gum, Xanthan 
gum, carrageenan gum, and proteins, Such as albumin, 
collagen, and gelatin. 
EXAMPLE 22 
Use of Alternative Photopolymerizable Moieties. 
Many photopolymerizable groups may be used to enable 
gelation. To illustrate a typical alternative Synthesis, a Syn 
thesis for PEG 1 K urethane methacrylate is described as 
follows: 
In a 250 ml round bottom flask, 10 g of PEG 1 K diol was 
dissolved in 150 ml benzene. 3.38 g of 
2-isocyanatoethylmethacrylate and 20 ul of dibutyltindilau 
rate were slowly introduced into the flask. The reaction was 
refluxed for 6 hours, cooled and poured into 1000 ml hexane. 
The precipitate was then filtered and dried under vacuum at 
60° C. for 24 hours. In this case, a methacrylate free radical 
polymerizable group was attached to the polymer via a 
urethane linkage, rather than an ester link as is obtained, e.g. 
when reacting with aryloxyl chloride. 
EXAMPLE 23 
Formation of Alginate-PLL-alginate Microcapsules with 
Photopolymerizable Polycations. 
Alginate-polylysine-alginate microcapsules are made by 
adsorbing, or coacervating, a polycation, Such as polylysine 
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(PLL), upon a gelled microsphere of alginate. The resulting 
membrane is held together by charge-charge interactions 
and thus has limited stability. To increase this stability, the 
polycation can be made photopolymerizable by the addition 
of a carbon-carbon double bond, for example. This can be 
used to increase the stability of the membrane by itself, or 
to react, for example, with photopolymerizable PEG to 
enhance biocompatibility. 
To illustrate the synthesis of such a photopolymerizable 
polycation, 1 g of polyallylamine hydrochloride was 
weighed in loo ml glass beaker and dissolved in 10 ml 
distilled water (DW). The pH of the polymer solution was 
adjusted to 7 using 0.2 M sodium hydroxide solution. The 
polymer was then Separated by precipitating in a large 
excess of acetone. It was then redissolved in 10 ml DW and 
the Solution was transferred to 50 ml round bottom flask. 0.2 
ml glycidyl methacrylate was slowly introduced into the 
reaction flask and the reaction mixture was stirred for 48 
hours at room temperature. The Solution was poured into 
200 ml acetone and the precipitate was separated by filtra 
tion and dried in vacuum. This macromer is useful in 
photochemically Stabilizing an alginate-PLL-alginate, both 
in the presence or in the absence of a Second polymerizable 
Species Such as a PEG diacrylate. 
In addition to use in encapsulating cells in materials. Such 
as alginate, Such photopolymerizable polycations may be 
useful as a primer or coupling agent to increase polymer 
adhesion to cells, cell aggregates, tissues and Synthetic 
materials, by virtue of adsorption of the photopolymerizable 
polymer bonding to the PEG photopolymerizable gel. 
EXAMPLE 24 
Encapsulation of Hemoglobin for Synthetic Erythrocytes. 
Hemoglobin in its free form can be encapsulated in PEG 
gels and retained by Selection of a PEG chain length and 
cross-link density which prevents diffusion. The diffusion of 
hemoglobin from the gels may be further impeded by the use 
of polyhemoglobin, which is a croSS-linked form of hemo 
globin. The polyhemoglobin molecule is too large to diffuse 
from the PEG gel. Suitable encapsulation of either native or 
crosslinked hemoglobin can be used to manufacture Syn 
thetic erythrocytes. The entrapment of hemoglobin in Small 
Spheres, less than five microns, of these highly biocompat 
ible materials should lead to enhanced circulation times 
relative to crosslinked hemoglobin or lipoSome encapsulated 
hemoglobin. 
Hemoglobin in PBS is mixed with the prepolymer in the 
following formulation: 
Hemoglobin at the desired amount 
PEG DA (MW 10000) 35% 
PEG DA (MW 1000) 5% 
PBS 60% 
with 2,2-dimethoxy, 2-phenyl acetophenone at 1.6% of the 
above Solution. 
This Solution is placed in mineral oil at a ratio of 1 part 
hemoglobin/prepolymer Solution to 5 parts mineral oil and is 
rapidly agitated with a motorized mixer to form an emulsion, 
which is then illuminated with a long-wavelength ultraviolet 
light (360 nm) for 5 minto crosslink the PEG prepolymer to 
form a gel. The molecular weight of the prepolymer can be 
selected to resist the diffusion of the hemoglobin from the 
gel, with Smaller PEG molecular weights giving less diffu 











crosslinked with PEG DA 1000, should possess the appro 
priate permselectivity to restrict hemoglobin diffusion, and 
it should possess the appropriate biocompatibility to circu 
late within the bloodstream. 
EXAMPLE 25 
Entrapment of Enzymes for Correction of Metabolic Disor 
derS and Chemotherapy. 
Congenital deficiency of the enzyme catalase causes 
acatalasemia. Immobilization of catalase in PEG gel net 
WorkS could provide a method of enzyme replacement to 
treat this disease. Entrapment of glucosidase can Similarly 
be useful in treating Gaucher's disease. Microspherical PEG 
gels entrapping urease can be used in extracorporeal blood 
to convert urea into ammonia. Enzymes Such as asparagi 
nase can degrade amino acids needed by tumor cells. Immu 
nogenicity of these enzymes prevents direct use for chemo 
therapy. Entrapment of Such enzymes in PEG gels, however, 
can Support Successful chemotherapy. A Suitable formulation 
can be developed for either slow release or no release of the 
enzyme. 
Catalase in PBS is mixed with the prepolymer in the 
following formulation: 
Catalase at the desired amount 
PEG DA (MW 10000) 35% 
PEG DA (MW 1000) 5% 
PBS 60% 
with 2,2-dimethoxy, 2-phenyl acetophenone at 1.6% of the 
above Solution. 
This Solution is placed in mineral oil at a ratio of 1 part 
catalase/prepolymer Solution to 5 parts mineral oil and is 
rapidly agitated with a motorized mixer to form an emulsion. 
This emulsion is illuminated with a long-wavelength ultra 
violet light (360 nm) for 5 min to crosslink the PEG 
prepolymer to form a gel. The mw of the prepolymer may be 
Selected to resist the diffusion of the catalase from the gel, 
with smaller PEG DA molecular weights giving less diffu 
SO. 
PEG DA of MW 10,000, further crosslinked with PEG 
DA 1000, should possess the appropriate permselectivity to 
restrict catalase diffusion, and it should possess the appro 
priate permselectivity to permit the diffusion of hydrogen 
peroxide into the gel-entrapped catalase to allow the enzy 
matic removal of the hydrogen peroxide from the blood 
Stream. Furthermore, it should possess the appropriate bio 
compatibility to circulate within the bloodstream. 
In this way, the gel is used for the controlled containment 
of a bioactive agent within the body. The active agent 
(enzyme) is large and is retained within the gel, and the 
agent upon which it acts (Substrate) is Small and can diffuse 
into the enzyme rich compartment. However, the active 
agent is prohibited from leaving the body or targeted body 
compartment because it cannot diffuse out of the gel com 
partment. 
EXAMPLE 26 
Cellular Microencapsulation for Evaluation of Anti-Human 
Immunodeficiency Virus Drugs. In Vivo. 
HIV infected or uninfected human T-lymphoblastoid cells 
can be encapsulated into PEG gels as described for other 
cells above. These microcapsules can be implanted in a 
nonhuman animal to create a test Sytem for anti-HIV drugs, 
and then treated with test drugs such as AZT or DDI. After 
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treatment, the microcapsu-les can be harvested and the 
encapsulated cells Screened for viability and functional 
normalcy using a fluorescein diacetate/ethidium bromide 
live/dead cell assay. Survival of infected cells indicates 
Successful action of the drug. Lack of biocompatibility is a 
documented problem in this approach to drug evaluations, 
but can be overcome by using the gels described herein. 
Modifications and variations are obvious from the fore 
going detailed description. Such modifications and varia 
tions are intended to come within the Scope of the following 
claims. 
We claim: 
1. A method for the treatment of a medical condition at a 
localized site, comprising the Steps in the following order: 
applying a polymerization initiator to the Site, 
applying a Substantially water-Soluble, degradable mac 
romer of at least 200 mw to the site, wherein the 
macromer comprises at least two crosslinkable 
Substituents, wherein at least one crosslinkable Sub 
Stituent can crosslink the macromer to other macromers 
under the influence of the initiator; and 
polymerizing the macromer to form a crosslinked poly 
meric material at the Site, 
wherein the crosslinked material assists in treatment of 
the medical condition. 
2. The method of claim 1 wherein the initiator is a 
free-radical initiator, and the Substituent is a free-radical 
polymerizable Substituent. 
3. The method of claim 1 wherein the initiator absorbs to 
a material at the Site. 
4. The method of claim 1 wherein excess or unabsorbed 
initiator is removed prior to application of macromer or is 




5. The method of claim 1 wherein the treatment comprises 
creating a barrier around a site Selected from the group 
consisting of a tissue, an organ, a cell, and a cluster of cells. 
6. The method of claim 5 wherein the barrier provides 
immunoisolation of the Site. 
7. The method of claim 5 wherein the barrier prevents the 
adhesion of the Site to another Surface. 
8. The method of claim 7 wherein the barrier prevents 
post-Surgical adhesions. 
9. The method of claim 6 wherein the barrier prevents the 
adhesion of nerves. 
10. The method of claim 5 wherein the barrier is applied 
to a blood vessel. 
11. The method of claim 1 where the macromer is in a 
Solution that further comprises a biologically active mol 
ecule. 
12. The method of claim 11 wherein the crosslinked 
polymeric meterial provides controlled release of the bio 
logically active molecule. 
13. The method of claim 1 wherein at least Some of the 
macromer is polycationic. 
14. The method of claim 1 wherein the crosslinked 
polymeric material is formed on a Surface of an implanted 
material. 
15. The method of claim 14 wherein the implanted surface 
is a Synthetic material. 
16. The method of claim 14 wherein the Surface is the 
Surface of a capsule Surrounding a tissue, an organ, a cell or 
a cluster of cells. 
17. The method of claim 1 wherein the crosslinked 
polymeric material adheres two Surfaces together. 
